Fig 3From: Volume-based growth tumor kinetics as a prognostic biomarker for patients with EGFR mutant lung adenocarcinoma undergoing EGFR tyrosine kinase inhibitor therapy: a case control studyROI placement in five serial CT slices of a patient with EGFR (+) lung adenocarcinoma in the right lower lobeBack to article page